Skip to content
‹ Back to IndustriesSciences

Bill Gates-Led Fund Backs Startup With Cheaper Way to Move Hydrogen

(Bloomberg) — A hydrogen molecule is tiny. So tiny, in fact, that trying to store and transport it via existing tanks and pipes can end up causing cracks in steel. If hydrogen is to become a clean fuel of the future, urgent technological solutions are needed to keep it in place and move it at…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share
Bill Gates-Led Fund Backs Startup With Cheaper Way to Move Hydrogen

Key takeaways

01

(Bloomberg) — A hydrogen molecule is tiny.

02

So tiny, in fact, that trying to store and transport it via existing tanks and pipes can end up causing cracks in steel.

03

If hydrogen is to become a clean fuel of the future, urgent technological solutions are needed to keep it in place and move it at…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

(Bloomberg) —

A hydrogen molecule is tiny. So tiny, in fact, that trying to store and transport it via existing tanks and pipes can end up causing cracks in steel. If hydrogen is to become a clean fuel of the future, urgent technological solutions are needed to keep it in place and move it at will.

Enter H2SITE, a Spanish startup, that promises to do just that. It’s secured 12.5 million euros ($13.23 million) in investments from Bill Gates-led Breakthrough Energy Ventures, French utility Engie SA and Norwegian oil giant Equinor ASA.

While there are existing methods to store and transport hydrogen, they can be prohibitively expensive, especially compared to moving around its carbonaceous cousin natural gas. H2SITE says that transporting hydrogen could cost as much as three times the cost of hydrogen production. The startup offers to provide that service at a fraction of a cost, if its technology can scale.

There are two modes in which H2SITE’s technology works. First is to use existing natural-gas pipelines to move hydrogen from where it’s produced to where it is consumed. These pipes can carry about 30% hydrogen when mixed with natural gas. The idea is that diluted hydrogen will be less corrosive on existing steel infrastructure. Freshly produced hydrogen is injected into a pipeline containing natural gas, close to where hydrogen is made, and then recovered using H2SITE’s filter where it needs to be consumed.

“It’s like being able to separate a great Bordeaux wine after it’s mixed with a common wine,” said Sebastien Arbola, executive vice president at Engie.

No sieve in the world can filter out hydrogen (or separate a Bordeaux from supermarket wine). So H2SITE makes use of some clever chemistry that exploits hydrogen’s liking for certain metals such as palladium. Under the right conditions of heat and pressure, a hydrogen atom on the surface of a palladium alloy can split apart and reform when the temperature and pressure are lower. That means H2SITE can filter hydrogen at 99.9% purity from a pipe carrying between 5% and 30% hydrogen with the rest being natural gas.

That’s not all. If it’s not pipes, hydrogen (H₂) is likely to be moved around in ships — not as itself but trapped within ammonia (NH₃) or methanol (CH₃OH). That’s because ammonia can be easily turned into a liquid and methanol is already a liquid. There are currently projects being developed in countries like Australia that have plenty of space for solar and wind farms where hydrogen is produced, converted to ammonia, moved on ships, and then hydrogen is recovered by undoing the chemical reaction.

Obviously, the process of converting hydrogen to ammonia and back is highly energy intensive. Bringing down the cost of ammonia cracking will be key to making large investments to scale up hydrogen production for exports, according to Anja-Isabel Dotzenrath, executive vice president of gas and low carbon energy at BP Plc. “What we need to address is the cost of ammonia cracking,” Dotzenrath said in a recent interview about the company’s plans for a green hydrogen hub in Australia.

H2SITE’s second mode of operation causes it to become a cracker for ammonia or methanol. All that needs to be done, according to Andrés Galnares, H2SITE’s chief executive officer, is to increase the number of palladium membranes and tweak the temperature and pressure at which the reactor is run.

“It is early days” for H2SITE, said Arbola. The startup has reactors that can be used to filter out 40 kilograms of hydrogen per day, whereas its commercial units will be able to handle 200kg and 500kg respectively. Once scaled up, Galnares says that the cost of filtering the clean-burning fuel will be about $0.80 per kilogram of hydrogen.

The startup already has three sites where the technology will be tested. In the UK, ammonia made with renewable hydrogen will be converted to hydrogen. In Spain, a consortium of energy companies and research centers will test the generation, injection and transportation of hydrogen, with H2SITE providing reactors for filtering. In France, H2SITE’s reactors will generate hydrogen for vehicles.

Engie’s Arbola is clear that in building out hydrogen infrastructure or repurposing existing pipelines, it’s important to ensure that hydrogen doesn’t leak. That’s because, while hydrogen isn’t a greenhouse gas, it can extend the life of existing potent warming gases like methane or cause the production of another greenhouse gas ozone.

With natural gas prices at such highs, clean energy research group BloombergNEF finds that green hydrogen is now cheaper than natural gas in eight European countries. That means you can expect more startups with technologies that work to make the hydrogen economy a reality.

–With assistance from Will Mathis.

To contact the author of this story:

Akshat Rathi in London at arathi39@bloomberg.net

More stories like this are available on bloomberg.com

© 2022 Bloomberg L.P.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512